Literature DB >> 10862617

The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates.

V Nurcombe1, C E Smart, H Chipperfield, S M Cool, B Boilly, H Hondermarck.   

Abstract

To explore how heparan sulfate (HS) controls the responsiveness of the breast cancer cell lines MCF-7 and MDA-MB-231 to fibroblast growth factors (FGFs), we have exposed them to HS preparations known to have specificity for FGF-1 (HS glycosaminoglycan (HSGAG A)) or FGF-2 (HSGAGB). Proliferation assays confirmed that MCF-7 cells were highly responsive to FGF-2 complexed with GAGB, whereas migration assays indicated that FGF-1/HSGAGA combinations were stimulatory for the highly invasive MDA-MB-231 cells. Quantitative polymerase chain reaction for the levels of FGF receptor (FGFR) isoforms revealed that MCF-7 cells have greater levels of FGFR1 and that MDA-MB-231 cells have greater relative levels of FGFR2. Cross-linking demonstrated that FGF-2/HSGAGB primarily activated FGFR1, which in turn up-regulated the activity of mitogen-activated protein kinase; in contrast, FGF-1/HSGAGA led to the phosphorylation of equal proportions of both FGFR1 and FGFR2, which in turn led to the up-regulation of Src and p125(FAK). MDA-MB-231 cells were particularly responsive to vitronectin substrates in the presence of FGF-1/HSGAGA, and blocking antibodies established that they used the alpha(v)beta(3) integrin to bind to it. These results suggest that the clustering of particular FGFR configurations on breast cancer cells induced by different HS chains leads to distinct phenotypic behaviors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10862617     DOI: 10.1074/jbc.M003038200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Temporal expression of fibroblast growth factor receptors during primary ligament repair.

Authors:  Simon M Cool; Charles P Snyman; Victor Nurcombe; Mark Forwood
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2003-12-23       Impact factor: 4.342

2.  A structural analysis of glycosaminoglycans from lethal and nonlethal breast cancer tissues: toward a novel class of theragnostics for personalized medicine in oncology?

Authors:  Amanda Weyers; Bo Yang; Dae Sung Yoon; Jong-Hwan Park; Fuming Zhang; Kyung Bok Lee; Robert J Linhardt
Journal:  OMICS       Date:  2012-03

3.  Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis.

Authors:  Dongfang Liu; Zachary Shriver; Ganesh Venkataraman; Yosuf El Shabrawi; Ram Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

4.  Effect of heparin on the biological properties and molecular signature of human mesenchymal stem cells.

Authors:  Ling Ling; Emily T Camilleri; Torben Helledie; Rebekah M Samsonraj; Drew M Titmarsh; Ren Jie Chua; Oliver Dreesen; Christian Dombrowski; David A Rider; Mario Galindo; Ian Lee; Wanjin Hong; James H Hui; Victor Nurcombe; Andre J van Wijnen; Simon M Cool
Journal:  Gene       Date:  2015-10-17       Impact factor: 3.688

5.  Chemical Tumor Biology of Heparan Sulfate Proteoglycans.

Authors:  Karthik Raman; Balagurunathan Kuberan
Journal:  Curr Chem Biol       Date:  2010-01-01

6.  Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas.

Authors:  Christoph Mundhenke; Kristy Meyer; Sally Drew; Andreas Friedl
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

7.  Regulation of endocytosis, nuclear translocation, and signaling of fibroblast growth factor receptor 1 by E-cadherin.

Authors:  David M Bryant; Fiona G Wylie; Jennifer L Stow
Journal:  Mol Biol Cell       Date:  2004-10-27       Impact factor: 4.138

8.  'Heparin'--from anticoagulant drug into the new biology.

Authors:  U Lindahl
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 2.916

9.  Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function.

Authors:  Johan Kreuger; Taro Matsumoto; Maarten Vanwildemeersch; Takako Sasaki; Rupert Timpl; Lena Claesson-Welsh; Dorothe Spillmann; Ulf Lindahl
Journal:  EMBO J       Date:  2002-12-02       Impact factor: 11.598

Review 10.  Functional proteomics of breast cancer for signal pathway profiling and target discovery.

Authors:  Hubert Hondermarck; Laurent Dollé; Ikram El Yazidi-Belkoura; Anne-Sophie Vercoutter-Edouart; Eric Adriaenssens; Jérôme Lemoine
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-10       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.